Contact us

News & Events

Press Releases

April 16, 2026

Alethio Therapeutics Unveils ATX‑011, a Breakthrough, Mutation‑Agnostic Antibody for Treating Essential Thrombocythemia – a c.$2B Market, and Strengthens Leadership to Accelerate Path to IND
February 6, 2026

Alethio Therapeutics Launches with New CEO and Chair to Advance Two Targeted Medicines for Myeloproliferative Neoplasms (Chronic Blood Cancers)

In the Media

Events